Please assess the completion status of the following clinical trial:

Trial Title: Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Double-blind phase: DSM-IV diagnosis of schizophrenia for at least 1 year~* experiencing an acute episode, with a total PANSS score at screening between 70 and 120~* agree to voluntary hospitalization for a minimum of 14 days~* willing and able to fill out self-administered questionnaires~* must be able to be compliant with self-administration of medication, or have consistent help/support available.~Open-label phase: have completed the 6 weeks of double-blind treatment or completed at least 21 days of treatment and discontinued due to lack of efficacy~* patient and investigator must agree that open-label treatment is in the best interest of the patient.~Exclusion Criteria:~* Double-blind phase: DSM-IV axis I diagnosis other than schizophrenia~* DSM-IV diagnosis of substance dependence within 6 months prior to screening evaluation (nicotine and caffeine dependence are not exclusionary)~* history of tardive dyskinesia or neuroleptic malignant syndrome (NMS)~* history of any severe preexisting gastrointestinal narrowing (pathologic or iatrogenic)~* previous history of a lack of response (2 adequate trials) to any antipsychotic~* significant risk of suicidal or violent behavior. Open-label extension: patients believed by the investigator to be at significant risk for suicidal or violent behavior~* received an injection of a depot antipsychotic since entry into the preceding double-blind phase.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).